The ETF concludes that bivalent original/Omicron BA.4-5 mRNA vaccines may be used for primary vaccination
16. Dezember 2022 – The EMA’s Emergency Task Force (ETF) considers that adapted mRNA bivalent vaccines targeting the original strain and Omicron BA.4-5 subvariants of SARS-CoV-2 may be used for primary (initial) vaccination. These vaccines are currently only authorised as boosters.
For more information, see here.